CERS6 and prostate carcinoma: This study confirmed that miR-16-5p targeted negative regulation of HMGA2 expression, and silencing CERS6-AS1 significantly inhibited HMGA2 expression by upregulating miR-16-5p, suggesting that CERS6-AS1/miR-16-5p/HMGA2 axis may exist in prostate cancer.